Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem Inc. submitted a Form 144 notice reporting a proposed resale of 21,492 shares of Common Stock originally issued as vested Restricted Stock Units dated 12/15/2021. The filing lists Robert Gagnon as the seller and shows 20,103 shares sold in the past three months.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 20,871 shares of common stock at $4.18 per share. According to the footnote, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, rather than a discretionary trade. Following the transaction, he directly owns 591,242 shares of Verastem common stock.
Verastem, Inc. Chief Financial Officer Daniel Calkins reported selling 4,089 shares of common stock. The transactions on June 22, 2026 consisted of open-market sales of 57 shares at $4.13 per share and 4,032 shares at $4.18 per share.
According to the footnote, these sales were made to satisfy statutory withholding requirements tied to the vesting of restricted stock units, meaning they were compensation-related rather than discretionary portfolio trades.
Verastem, Inc. reported detailed preliminary data for VS-7375, its investigational oral KRAS G12D (ON/OFF) inhibitor, from the ongoing Phase 1/2 TARGET-D 101 trial in advanced solid tumors. Doses from 400 mg to 900 mg once daily showed anti-tumor activity in metastatic pancreatic ductal adenocarcinoma, metastatic colorectal cancer and advanced non-small cell lung cancer, both as monotherapy and in combinations.
At the June 12, 2026 cutoff, VS-7375 demonstrated a favorable safety profile at 600 mg once daily in 57 patients and 900 mg once daily in 25 patients, with mostly low-grade gastrointestinal side effects and limited Grade 3 events. In metastatic pancreatic cancer, 93% of 14 patients at 900 mg once daily achieved more than a 50% reduction in the tumor marker CA19-9, and individual case examples showed rapid, deep radiographic responses.
More than 150 patients have been enrolled across dose-escalation and expansion cohorts. Verastem plans to complete enrollment in three Phase 2 TARGET-D trials by the end of 2026 and to enroll the first patients in three Phase 3 pivotal trials in first-line pancreatic, colorectal and lung cancer by the first half of 2027. The company also announced its intent to enter into a collaboration with Erasca, Inc. to evaluate VS-7375 in combination with ERAS-0015, initially in preclinical models and potentially in future clinical trials.
Verastem, Inc. filed a Form 144 notifying a proposed sale of 20,871 shares of Common Stock. The filing shows a prior sale of 806 shares on 05/04/2026 and lists 87,873,639 shares outstanding as of 06/22/2026.
Verastem Oncology reported updated early-stage results from its RAMP 205 Phase 1b/2a trial in first-line metastatic pancreatic ductal adenocarcinoma. In 29 patients treated at the recommended Phase 2 dose with avutometinib plus defactinib and standard chemotherapy, 90% had metastatic disease at diagnosis.
As of a June 5, 2026 data cutoff and 9.8 months median follow-up, the combination showed an 86% overall survival rate at 6 months, a 68% progression-free survival rate at 6 months, and a confirmed objective response rate of 52% (15 of 29 patients). Most patients (83%) experienced tumor shrinkage, nine remained on treatment, and no new safety signals were observed.
The company also began dosing the first patient in TARGET-D 201, a Phase 2 registration-directed trial of VS-7375, an investigational oral KRAS G12D inhibitor, given at 900 mg daily as monotherapy and with full-dose cetuximab in second-line metastatic pancreatic cancer.
BAILEY MICHAEL P reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michael P. Bailey reported an equity award of 108,000 shares of Common Stock in the form of restricted stock units at no cash cost. The grant consists of 36,000 RSUs as an annual grant and 72,000 RSUs as an initial grant under Verastem's Amended and Restated 2021 Equity Incentive Plan.
The 36,000 annual grant RSUs vest in twelve monthly installments from June 2026 through May 2027, tied to continued board service. The 72,000 initial grant RSUs vest in twelve quarterly installments starting on May 21, 2026, and are scheduled to fully vest three years from that date, also contingent on continued service. Following this award, Bailey directly holds 108,000 shares/RSUs.
Verastem, Inc. director Michael P. Bailey has filed an initial SEC Form 3 as a reporting person for the company. The filing does not report any insider transactions and shows no derivative positions, serving as a baseline disclosure of his status as a director.
Tollefson Karin Anna reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Karin Anna Tollefson received a grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were awarded under Verastem’s Amended and Restated 2021 Equity Incentive Plan and require her continued service as a director to vest.
The RSUs vest in 12 substantially equal monthly installments, with the first 11 vesting on the last day of each month from June 2026 through April 2027. The final installment vests on the earlier of the day before Verastem’s 2027 Annual Meeting of Stockholders or May 31, 2027. After this grant, Tollefson directly holds 52,666 shares of Verastem Common Stock, including the granted RSUs.